The Pakistan Credit Rating Agency (PACRA) has maintained the entity ratings of AGP Limited (AGP) at 'A+' for the long term and 'A1' for the short term, with a stable outlook as of October 22, 2026.
According to PACRA, the ratings reflect AGP's established position in Pakistan's pharmaceutical sector and its strategic importance within the OBS Group. However, sustaining these ratings remains contingent on continuous topline growth and profitability.
| Metric | 1HCY26 | CY25 |
|---|---|---|
| Consolidated Revenue (PKR) | 11.53 bn | 28.89 bn |
| Gross Profit Margin | 59% | - |
| Net Profit Margin | 14% | - |
AGP reported consolidated revenue of PKR 11.53 billion in 1HCY26, down about 20% on an annualized basis from PKR 28.89 billion in CY25. PACRA attributed the decline to lower exports following the Afghanistan border closure, a shorter winter season, and softer product demand.
Despite lower revenue, AGP maintained strong profit margins, with gross and net margins holding at 59% and 14%, respectively. PACRA noted that the deregulation of non-essential medicine prices provided the industry leverage to manage cost inflation.
Read the full story on the original publisher’s website.
Open original article